Skip to main content

Market Overview

ATEC Reports First Quarter Financial Results and Recent Corporate Highlights

  • U.S. Revenue Growth Accelerates to 50%

  • Revenue Growth Averages ~33% Over Past Eight Quarters

CARLSBAD, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (NASDAQ:ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended March 31, 2021, and recent corporate highlights.

First Quarter 2021 Financial Results

  Quarter Ended March 31, 2021
Total revenue $44.1 million
U.S. revenue $43.7 million
U.S. gross margin 73.1%
Non-GAAP U.S. gross margin 77.9%
Operating expenses $50.9 million
Non-GAAP operating expenses $42.0 million
Operating loss ($19.0) million
Non-GAAP adjusted EBITDA ($4.1) million
Ending cash balance $191.1 million

Recent Highlights

  • Expanded contribution from new products to 77% of U.S. revenue, up from 56% in Q1 2020;
  • Continued sales network transformation delivering 60% year-over-year revenue growth from strategic distribution;
  • Secured clearance from French regulatory authority for tender offer to acquire EOS imaging, S.A. ("EOS"), allowing the transaction – which will advance ATEC clinical prowess with improved information from diagnosis to follow-up – to move forward.

"With revenue growth of 50% in the first quarter, ATEC's market share expansion continues," said Pat Miles, Chairman and Chief Executive Officer. "Our relentless focus on improving the clinical experience in spine is now propelling industry-leading growth. Market-shaping innovation, integrated with unprecedented intra-operative information, is compelling an increasing number of surgeons and exclusive distributors to partner with ATEC. That growth is being amplified as the introduction of distinct products and procedures throughout our portfolio increases revenue per surgery and inspires broader adoption. Still, there is vast opportunity ahead of us to advance spine surgery, and as spine's most experienced students, we know that ATEC's best is yet to come!"

Financial Outlook for the Full Year 2021

The Company expects total revenue for the fiscal year ended December 31, 2021, to approximate $190 million, which includes U.S. revenue of approximately $188 million. Revenue guidance reflects expected U.S. revenue growth of roughly 33% compared to 2020, driven by continued launches of novel procedures, products, and the revitalization of the Company's distribution network. Total revenue guidance contemplates the anticipated wind-down of the Company's international supply agreement on August 31, 2021. ATEC expects to update guidance to reflect the positive impact of EOS imaging when the Company reports second quarter 2021 financial results, once the transaction is finalized.

Investor Conference Call

ATEC will present these results via a live webcast today at 1:30 p.m. PT / 4:30 p.m. ET. The live webcast can be accessed by visiting the Investor Relations section of ATEC's corporate website at

To dial in to the webcast, please visit the following registration link: Once registered, participants will be provided with access details and a registrant ID.

A replay of the webcast will remain available through the Investor Relations section of ATEC's Corporate Website at for twelve months. In addition, a replay of the audiocast will be available beginning two hours after the call's completion until May 13, 2021. The replay dial-in numbers are (800)585-8367 for domestic callers and (416)621-4642 for international callers. Please use the replay conference ID number 9350774.

Non-GAAP Financial Information

To supplement the Company's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company reports certain non-GAAP financial measures, including non-GAAP U.S. gross margin, non-GAAP operating expenses, non-GAAP operating loss, and non-GAAP Adjusted EBITDA. The Company believes that these non-GAAP financial measures provide investors with an additional tool for evaluating the Company's core performance, which management uses in its own evaluation of continuing operating performance, and a baseline for assessing the future earnings potential of the Company. The Company's non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in the Company's industry, as other companies in the industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. Non-GAAP financial results should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Included below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

About Alphatec Holdings, Inc.

Alphatec Holdings, Inc. (ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the SafeOp Neural InformatiX System to safely and reproducibly treat spine's various pathologies and achieve the goals of spine surgery. ATEC's vision is to become the Standard Bearer in Spine. For more information, visit us at

Forward Looking Statements 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company's revenue and growth outlook, planned commercial launches, product introduction and surgeon adoption, salesforce revitalization and growth of strategic distribution network, turning the Company into a growth organization, creating future market disruption and market share expansion, the Company's future ability to finance its operations and statements about the anticipated acquisition (and potential impacts therefrom) of EOS imaging, S.A.  Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the impact of COVID-19 pandemic on the Company's business and the economy; the uncertainty of success in developing new products or products currently in the Company's pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for Company's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any litigation asserted against the Company; and uncertainties and risks related to the proposed tender offer EOS Imaging, S.A. and integration thereafter. The words "believe," "will," "should," "expect," "intend," "estimate," "look forward" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. 

Investor/Media Contact:

Tina Jacobsen, CFA
Investor Relations
(760) 494-6790

Company Contact:
J. Todd Koning
Chief Financial Officer

  (in thousands, except per share amounts)  
    Three Months Ended          
    March 31,          
      2021       2020            
    (unaudited)   (unaudited)          
  Revenue from U.S. products $ 43,716     $ 29,070            
  Revenue from international supply agreement   405       1,045            
  Total revenues   44,121       30,115            
  Cost of revenues   12,263       9,084            
  Gross profit   31,858       21,031            
  Operating expenses:                
  Research and development   5,801       4,170            
  Sales, general and administrative   40,426       27,582            
  Litigation-related   3,335       2,643            
  Amortization of acquired intangible assets   172       172            
  Transaction-related   1,012       4,272            
  Restructuring   158                  
  Total operating expenses   50,904       38,839            
  Operating loss   (19,046 )     (17,808 )          
  Interest and other expense, net:                
  Interest expense, net   (1,938 )     (2,874 )          
  Other expenses   (1,889 )                
  Total interest and other expenses, net   (3,827 )     (2,874 )          
  Loss from continuing operations before taxes   (22,873 )     (20,682 )          
  Income tax provision   30       40            
  Loss from continuing operations   (22,903 )     (20,722 )          
  Net loss $ (22,903 )   $ (20,722 )          
  Net loss per share, basic and diluted $ (0.26 )   $ (0.33 )          
  Shares used in calculating basic and diluted net loss per share   87,223       62,568            
  Stock-based compensation included in:              
  Cost of revenues $ 95     $ 107            
  Research and development   498       390            
  Sales, general and administrative   3,881       3,071            
    $ 4,474     $ 3,568            

(in thousands)
  March 31, 2021   December 31, 2020
Current assets:      
Cash $ 191,137   $ 107,765
Accounts receivable, net   25,751     23,527
Inventories, net   57,376     46,001
Prepaid expenses and other current assets   3,433     5,439
Withholding tax receivable from Officer   1,076     1,076
Current assets of discontinued operations   348     352
Total current assets   279,121     184,160
Property and equipment, net   56,124     36,670
Right-of-use asset   21,704     1,177
Goodwill   13,897     13,897
Intangible assets, net   24,129     24,720
Debt securities   1,313    
Equity securities   7,619    
Other assets   541     541
Noncurrent assets of discontinued operations   55     58
Total assets $ 404,503   $ 261,223
Current liabilities:      
Accounts payable $ 26,416   $ 17,599
Accrued expenses   36,730     35,231
Current portion of long-term debt   5,374     4,200
Current portion of lease liability   1,486     885
Current liabilities of discontinued operations   143     397
Total current liabilities   70,149     58,312
Total long term liabilities   70,621     49,428
Redeemable preferred stock   23,603     23,603
Contingently redeemable common stock   131,838    
Stockholders' equity   108,292     129,880
Total liabilities and stockholders' equity $ 404,503   $ 261,223
    -     -

(in thousands)  
      Three Months Ended      
      March 31,      
        2021       2020        
      (unaudited)   (unaudited)      
  Operating expenses   $ 50,904     $ 38,839        
  Stock-based compensation     (4,379 )     (3,461 )      
  Litigation-related expenses     (3,335 )     (2,643 )      
  Restructuring expenses     (158 )            
  Transaction-related expenses     (1,012 )     (4,272 )      
  Non-GAAP operating expenses   $ 42,020     $ 28,463        
      Three Months Ended      
      March 31,      
        2021       2020        
      (unaudited)   (unaudited)      
  Operating loss, as reported   $ (19,046 )   $ (17,808 )      
  Add back significant items:              
  Stock-based compensation     4,474       3,568        
  Litigation-related expenses     3,335       2,643        
  Restructuring expenses     158              
  Transaction-related expenses     1,012       4,272        
  Excess & obsolete charges     2,096       1,722        
  Adjusted operating loss     (7,971 )     (5,603 )      
  Operating loss, as reported   $ (19,046 )   $ (17,808 )      
    Depreciation     3,409       2,014        
    Amortization of intangible assets     441       440        
  EBITDA     (15,196 )     (15,354 )      
  Add back significant items:              
  Stock-based compensation     4,474       3,568        
  Litigation-related expenses     3,335       2,643        
  Restructuring expenses     158              
  Transaction-related expenses     1,012       4,272        
  Excess & obsolete charges     2,096       1,722        
  Adjusted EBITDA   $ (4,121 )   $ (3,149 )      

(in thousands, except percentages)
    Three Months Ended  
    March 31,  
      2021       2020    
  Revenues by source (unaudited)   (unaudited)  
  Revenue from U.S. products $ 43,716     $ 29,070    
  Revenue from international supply agreement   405       1,045    
  Total revenues $ 44,121     $ 30,115    
  Gross profit (loss) by source        
  Gross profit from U.S. products $ 31,975     $ 20,954    
  Gross profit (loss) from international supply agreement   (117 )     77    
  Total gross profit $ 31,858     $ 21,031    
  Gross profit (loss) margin by source        
  Gross profit margin from U.S. products   73.1 %     72.1 %  
  Gross profit (loss) margin from international supply agreement   -28.9 %     7.4 %  
  Total gross profit margin   72.2 %     69.8 %  
(in thousands, except percentages)
    Three Months Ended  
    March 31,  
      2021       2020    
    (unaudited)   (unaudited)  
  GAAP-based gross profit from U.S. products $ 31,975     $ 20,954    
  Add: non-cash excess and obsolete charges   2,096       1,722    
  Non-GAAP gross profit from U.S. products $ 34,071     $ 22,676    
  GAAP-based gross margin from U.S. products   73.1 %     72.1 %  
  Add: non-cash excess and obsolete charges   4.8 %     5.9 %  
  Non-GAAP gross margin from U.S. products   77.9 %     78.0 %  




Primary Logo

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at